Drug intelligence / Profile preview

liposome-CHX-A″-DTPA-213Bi-7.16.4

Development stage: Preclinical
Lead developer: National Cancer Institute
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**liposome-CHX-A″-DTPA-213Bi-7.16.4** is an experimental HER2/neu-targeted alpha radioimmunotherapy for metastatic breast cancer. It consists of approximately 100-nm liposomes bearing the rat anti-HER2/neu monoclonal antibody 7.16.4 and the alpha-emitting radionuclide bismuth-213, chelated by CHX-A″-DTPA. Antibody-mediated binding to HER2/neu-expressing tumor cells localizes high-linear-energy-transfer alpha radiation, causing lethal DNA damage over a short tissue range. The construct showed activity against early micrometastatic mammary carcinoma in a rat/neu transgenic mouse model following intravenous administration, but it has not been reported as a clinical-stage or marketed product. ([publications.jrc.ec.europa.eu](https://publications.jrc.ec.europa.eu/repository/handle/JRC56313))

Other names: (213)Bi-labeled 7.16.4 immunoliposome213Bi-liposome-CHX-A″-DTPA-7.16.4liposome + CHX-A''-DTPA + 213Bi + 7.16.4

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on liposome-CHX-A″-DTPA-213Bi-7.16.4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on liposome-CHX-A″-DTPA-213Bi-7.16.4.

Explore the full profile